Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P10916
UPID:
MLRV_HUMAN
Alternative names:
Cardiac myosin light chain 2; Myosin light chain 2, slow skeletal/ventricular muscle isoform; Ventricular myosin light chain 2
Alternative UPACC:
P10916; Q16123
Background:
Myosin regulatory light chain 2, ventricular/cardiac muscle isoform, known as Cardiac myosin light chain 2, plays a pivotal role in heart development and function. It is essential for heart muscle contraction, influencing myosin kinetics and enhancing cardiac contractility through phosphorylation. This protein is integral to maintaining heart rhythm and force, adapting to physiological demands.
Therapeutic significance:
Linked to diseases such as Cardiomyopathy, familial hypertrophic, 10, and Myopathy, myofibrillar, 12, infantile-onset, with cardiomyopathy, this protein's genetic variants underscore its clinical importance. Understanding its role could lead to breakthroughs in treating heart-related disorders, offering hope for targeted therapies that address the underlying genetic causes.